Nilotinib, bafetinib, dasatinib, and bosutinib have been developed as second-generation BCR-ABL inhibitors, with superior potency over imatinib, to treat adult CML patients with imatinib resistance.8–11. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.